<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04077255</url>
  </required_header>
  <id_info>
    <org_study_id>31973</org_study_id>
    <nct_id>NCT04077255</nct_id>
  </id_info>
  <brief_title>EGFR/FGFR-targeted Therapy for Gastric Cancer</brief_title>
  <official_title>Anti-EGFR Antibody (GC-1118) or FGFR Inhibitor (Rogaratinib) in Combination With Weekly Paclitaxel as a Second-line Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas With Amplifications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on targeted NGS panel results, metastatic gastric cancer patients with gene
      amplifications will receive either anti-EGFR antibody (GC-1118) or FGFR inhibitor
      (rogaratinib) in combination with weekly paclitaxel as a second-line therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive each treatment if the gastric cancer tissue sample reveals one of
      the following somatic aberrations:

        1. Anti-EGFR (GC-1118) in combination with weekly paclitaxel EGFR-amplification or strong
           (3+) EGFR immunostaining

        2. FGFR inhibitor (rogaratinib) in combination with weekly paclitaxel Gene amplifications,
           mRNA overexpression, oncogenic mutations, or gene fusions involving FGFR1, FGFR2, or
           FGFR3
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Response rate will be assessed at 8 weeks.</time_frame>
    <description>Response rate will be assessed using CT/MRI according to RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of enrollment until the date of first documented progression or the date of death from any cause, whichever came first, will be assessed up to 1 year.</time_frame>
    <description>Time from date of enrollment until the date of first documented progression or the date of death from any cause, whichever came first, will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Adenocarcinoma of the Stomach</condition>
  <arm_group>
    <arm_group_label>Anti-EGFR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous GC-1118 in combination with weekly paclitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FGFR inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral rogaratinib in combination with weekly paclitaxel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-EGFR antibody in combination with weekly paclitaxel</intervention_name>
    <description>Intravenous GC-1118 in combination with weekly paclitaxel for EGFR-amplified cancer cancers as a second-line therapy</description>
    <arm_group_label>Anti-EGFR</arm_group_label>
    <other_name>GC-1118 in combination with weekly paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FGFR inhibitor in combination with weekly paclitaxel</intervention_name>
    <description>Oral rogaratinib in combination with weekly paclitaxel for metastatic cancer cancer with FGFR activation as a second-line therapy</description>
    <arm_group_label>FGFR inhibitor</arm_group_label>
    <other_name>Rogaratinib in combination with weekly paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria

          1. Histologically-proven gastric and gastroesophageal junction adenocarcinoma

          2. Refractory to first-line chemotherapy for metastatic disease

          3. Presence of at least 1 measurable lesion according to RECIST version 1.1

          4. Molecular profiles of tumor tissue:

        (Anti-EGFR substudy) EGFR-amplification or strong (3+) EGFR immunostaining (FGFR inhibitor
        substudy) Gene amplifications, mRNA overexpression, oncogenic mutations, or gene fusions
        involving FGFR1, FGFR2, or FGFR3

        Key exclusion criteria

        1.Prior exposure to taxane or EGFR/FGFR-targeted therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hark K Kim, M.D.,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hark K Kim, M.D.,Ph.D</last_name>
    <phone>+82-31-920-2238</phone>
    <email>hkim@ncc.re.kr</email>
  </overall_contact>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>August 30, 2019</last_update_submitted>
  <last_update_submitted_qc>August 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Hark Kyun Kim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>EGFR</keyword>
  <keyword>FGFR2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

